MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ:NXTC)

9.760 -0.420 (-4.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NextCure, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 
From NextCure
Via GlobeNewswire
News headline image
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure (NXTC) Q2 Loss Widens 71% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus ↗
U.S. stock futures swung between gains and losses on Friday after ending on a mixed note on Thursday. Futures were mixed. 
Via Benzinga
News headline image
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment ↗
NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility. 
Via Stocktwits
News headline image
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease ↗
NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical data for NC605. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
News headline image
Monday's session: top gainers and losers ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline ↗
The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. 
Via Stocktwits
News headline image
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
From NextCure
Via GlobeNewswire
News headline image
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story